Literature DB >> 7155637

Prognostic factors in myelofibrosis.

A Manoharan, R C Smart, W R Pitney.   

Abstract

The prognostic significance of spleen size, hemoglobin level (Hb), platelet count and hemopoietic cellularity of the bone marrow was assessed in 33 patients with myelofibrosis. Of these 4 parameters, only the Hb (P less than 0.01) and bone marrow cellularity (P less than 0.001) were found to be useful indicators of prognosis. Patients with Hb greater than 10 g/dl had a median survival greater than 110 mth while those with Hb less than 10 g/dl had a median survival of 22.5 mth; patients with hemopoietic hypercellularity in the bone marrow had a median survival greater than 110 mth while those with a normo- or hypocellularity had a median survival of 20.5 mth. There was significant correlation (P less than 0.01) between the marrow cellularity and the Hb level; 71% of patients with a normo- or hypocellular marrow had Hb less than 10 g/dl, while 79% of those with a hypercellular marrow had Hb greater than 10 g/dl.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7155637     DOI: 10.3109/00313028209092127

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  3 in total

1.  Myelofibrosis arising in treated histiocytosis X.

Authors:  D J Sartoris; D Resnick
Journal:  Eur J Pediatr       Date:  1985-07       Impact factor: 3.183

2.  Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival.

Authors:  S Rupoli; L Da Lio; S Sisti; G Campanati; A Salvi; M F Brianzoni; S D'Amico; A Cinciripini; P Leoni
Journal:  Ann Hematol       Date:  1994-04       Impact factor: 3.673

3.  The value of bone marrow, liver, and spleen imaging in diagnosis, prognostication, and follow-up monitoring of myeloproliferative neoplasms: a systematic review.

Authors:  Stefanie Slot; Niels W C J van de Donk; René H J Otten; Bouke J H Boden; Josée Zijlstra; Pieter G H M Raijmakers; Sonja Zweegman
Journal:  Cancer Imaging       Date:  2021-04-20       Impact factor: 3.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.